MCE 的所有產品僅用作科學研究或藥證申報，我們不為任何個人用途提供產品和服務。

INCB3344

產品活性：INCB3344 是一種有效的 CCR2 拮抗劑，拮抗結合活性時，IC₅₀ 為 5.1 nM (hCCR2) 和 9.5 nM (mCCR2)，拮抗趨化活性時，IC₅₀ 為 3.8 nM (hCCR2) 和 7.8 nM (mCCR2)。

研究領域：GPCR/G Protein  |  Immunology/Inflammation

作用靶點：CCR

In Vitro: INCB3344 is a potent antagonist towards rat and cynomolgus CCR2 as well, displaying IC₅₀ values of 7.3 and 16 nM in binding antagonism and 2.7 and 6.2 nM in antagonism of chemotaxis activity, respectively. INCB3344 is a selective hCCR2 antagonist, exhibiting IC₅₀ values of more than 1 μM against a panel of >50 ion channels, transporters, chemokine receptors and other selected GPCRs. It is also a selective mCCR2 antagonist, showing IC₅₀ values of >1 μM and >3 μM against murine CCR1 and murine CCR5, respectively, the two most homologous chemokine receptors to mCCR2. Characterization of the pharmacological activity of INCB3344 is first evaluated by testing its ability to inhibit CCL2 binding to CCR2 in a whole cell binding assay using a murine monocyte cell line, WEHI-274.1 and ¹²⁵I-labeled mCCL2 as a tracer. The binding IC₅₀ of INCB3344 in this assay is determined to be 10±5 nM, and inhibition of >90% binding is observed at a concentration of 90 nM.

In Vivo: When administered intravenously to CD-1 mice, INCB3344 exhibits a high clearance and a moderate volume of distribution, resulting in a short half life of 1 h. Despite its high clearance, however, good oral exposure is achieved, with an AUC at 2664 nM h at a dose of 10 mg/kg. The oral bioavailability is 47%. By comparison, slightly better oral exposure (AUC=3888 nM h) is obtained when administered orally to Balb/c mice at the same dose. This PK property, couple with its potent anti-mCCR2 activity and good selectivity, makes this compound suitable for model studies in rodents. INCB3344 prevents Deoxycorticosterone acetate/salt-induced changes in vascular expression of CCR2. In a separate series of experiments, CCR2 expression is elevated (≈1.5-fold higher) in aortas from mice that receive INCB3344 from days 7 to 21 of the Deoxycorticosterone acetate/salt treatment period compare with sham animals; however, this level of CCR2 expression is significantly lower than that observed in the vehicle-treated group (P<0.05, n=6). Likewise, increased expression of its receptor ligand CCL2 in Deoxycorticosterone acetate/salt-treated mice is blunted in mice receiving INCB3344 (P<0.05, n=6). By contrast, levels of CCL7, CCL8, and CCL12 are elevated to similar extents in Deoxycorticosterone acetate/salt-treated mice receiving vehicle or INCB3344.

相關產品：Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  Small Molecule Immuno-Oncology Compound Library  |  Endocrinology Compound Library  |  Orally Active Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Chemokine Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  DAPTA  |  BMS-753426  |  BMS-813160  |  JNJ-27141491  |  CCR5 antagonist 2  |  AZD-5672  |  CCR5 antagonist 3  |  Vercirnon  |  GSK2239633A  |  Bindarit  |  Leronlimab  |  Maraviroc  |  Plozalizumab  |  AZD-1678  |  CCR4 antagonist 3-1  |  Aplaviroc hydrochloride  |  CCR1 antagonist 6  |  J-113863  |  CCR1 antagonist 11 hydrochloride  |  AZD2423  |  AZD2098  |  RS102895 hydrochloride  |  LMD-009  |  Carlumab  |  Vicriviroc maleate  |  CKLF1-C19  |  ALK4290  |  CCR1 antagonist 10  |  ZK756326 dihydrochloride  |  INCB 3284 dimesylate

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種*僅有化合物庫，我們致力于為*科研客戶提供前沿的高品質小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領；
•   產品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產品，廣泛應用于新藥研發、生命科學等科研項目；
•   提供虛擬篩選，離子通道篩選，代謝組學分析檢測分析，藥物篩選等專業技術服務；
•   設有專業的實驗中心和嚴格的質控、驗證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質檢報告，確保產品的高純度、高品質；
•   產品的生物活性多經各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專業團隊跟蹤新的制藥及生命科學研究進展，為您提供*新的活性化合物；
•   與世界各大制藥公司及*科研機構建立了長期的合作。